Chemomab Therapeutics Ltd ADR (CMMB) Stock Price, Quote & News

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemi...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 77 331 0156

Website: www.chemomab.com

Address:

Building C, 10th Floor 10 Habarzel Street, Tel Aviv-Yafo, Israel

Psuedo_Doji Jun. 4 at 7:16 PM

$CMMB in Gwen we trust

1 · Reply

Stockhunter008 Jun. 4 at 5:57 PM

$CMMB if nothing else, the recent $CMMB BOD changes are evidence that this company will undoubtedly be monetized

1 · Reply

DLTT4489 Jun. 4 at 5:47 PM

$CMMB he lost tons of money on $QNCX and will do same here. Keep covering each other pumpers 🤣🤣🤣

0 · Reply

DLTT4489 Jun. 4 at 5:44 PM

$CMMB @W2Cap will understand that bought wrong stock soon. Look ar shreyvakil answer. I've been saying these for years and no one believed it, so you deserve to be rubbed by mafia. 😜😜

0 · Reply

DLTT4489 Jun. 4 at 5:36 PM

$CMMB is @Snptrader idiot still posting BS here?? What about @shreyvakil ?? 😅😅

0 · Reply

JoeShmoDoe Jun. 3 at 8:29 PM

$CMMB lol, check history. People should know that no one buys this load of shit.

0 · Reply

JoeShmoDoe Jun. 3 at 8:26 PM

$CMMB lol, the joke happened here. No one literally buys this shit.

0 · Reply

DLTT4489 Jun. 3 at 6:18 PM

$CMMB you don't know those MFrs who's sitting in their office in !z r@el and keep stealing your money. They are blood suckers

0 · Reply

Tigerfromasia Jun. 3 at 2:45 PM

$CMMB I do not believe in this company’s management but appointing Gwen Melincoff is one of the best decision that company has made. She was involved in numerous m&a, buyout, partnership before. I would not be too excited about it but this could possibly mean something.

2 · Reply

W2Cap Jun. 3 at 11:11 AM

$CMMB - The senior leader buying on open market means there's no immediate deal. - No update on BTD submission. - Posters, posters, and more posters in Barcelona and Lisbon. Nothing new or exciting in any of them. - No communication to investors Sorry but these guys are fucking retarded. Great drug, the fact that they can't do a deal for over a year is insane.

3 · Reply

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 8:00 AM EDT - 21 days ago

Chemomab Therapeutics Earnings release: Q1 2026

2026-03-19T12:11:46.000Z - 2 months ago

Chemomab Therapeutics sees cash runway through 1Q27

2026-03-19T12:05:34.000Z - 2 months ago

Chemomab Therapeutics reports FY25 EPS (1c) vs. (4c) last year

Mar 19, 2026, 8:00 AM EDT - 2 months ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Mar 19, 2026, 8:00 AM EDT - 2 months ago

Chemomab Therapeutics Annual report: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 2 months ago

Chemomab Therapeutics Earnings release: Q4 2025

Mar 1, 2026, 6:00 AM EST - 3 months ago

Chemomab Therapeutics Slides: Corporate presentation

Feb 26, 2026, 8:00 AM EST - 3 months ago

Chemomab Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 8:00 AM EST - 3 months ago

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

2025-12-02T13:15:59.000Z - 6 months ago

Chemomab Therapeutics announces results of its Phase 2 SPRING trial

Dec 2, 2025, 8:00 AM EST - 6 months ago

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Nov 24, 2025, 8:00 AM EST - 6 months ago

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Nov 21, 2025, 7:00 AM EST - 6 months ago

Chemomab Therapeutics Earnings release: Q3 2025

2025-11-20T13:05:27.000Z - 7 months ago

Chemomab Therapeutics reports Q3 EPS (0.4c) vs (1c) last year

Nov 20, 2025, 8:00 AM EST - 7 months ago

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-06T13:47:57.000Z - 7 months ago

Chemomab announces presentations at AASLD 2025 on nebokitug data

Nov 6, 2025, 8:00 AM EST - 7 months ago

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

2025-09-12T16:55:11.000Z - 9 months ago

Chemomab Therapeutics management to meet with Maxim

Sep 5, 2025, 7:00 AM EDT - 9 months ago

Chemomab Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-08-27T16:21:06.000Z - 10 months ago

Chemomab Therapeutics price target raised to $25 from $10 at Oppenheimer

2025-08-25T23:50:06.000Z - 10 months ago

Chemomab Therapeutics Ltd – ADR trading halted, news pending

Aug 21, 2025, 8:00 AM EDT - 10 months ago

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

2025-08-14T12:11:23.000Z - 10 months ago

Chemomab Therapeutics reports Q2 EPS 0.4c vs 0.013c last year

Aug 14, 2025, 8:00 AM EDT - 10 months ago

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 6:00 PM EDT - 10 months ago

Chemomab Therapeutics Earnings release: Q2 2025

2025-07-31T17:55:26.000Z - 11 months ago

Chemomab Therapeutics management to meet with Maxim

2025-06-30T14:35:01.000Z - 1 year ago

Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

2025-06-11T12:05:42.000Z - 1 year ago

Chemomab obtained feedback from two recent FDA meetings on nebokitug

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

2025-06-03T12:05:13.000Z - 1 year ago

Chemomab announces nebokitug awarded new patent protection in China, Russia

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

2025-05-16T11:36:15.000Z - 1 year ago

Chemomab Therapeutics price target lowered to $10 from $11 at Oppenheimer

2025-05-15T12:16:43.000Z - 1 year ago

Chemomab Therapeutics reports Q1 EPS $0.007 vs $0.014 last year

May 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Earnings release: Q1 2025

2025-05-05T12:11:50.000Z - 1 year ago

Chemomab Therapeutics announces presentation of Phase 2 data of CM-101

May 5, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

2025-04-28T12:31:07.000Z - 1 year ago

Chemomab Therapeutics reports new clinical data at EASL 2025 on nebokitug

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

2025-04-15T12:23:08.000Z - 1 year ago

Chemomab Therapeutics appoints Weiner as interim CMO, Lawler as CDO

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces New Medical and Clinical Appointments

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Mar 6, 2025, 8:00 AM EST - 1 year ago

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Mar 3, 2025, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Mar 3, 2025, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Annual report: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Earnings release: Q4 2024

Feb 19, 2025, 7:00 AM EST - 1 year ago

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Feb 11, 2025, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Nov 19, 2024, 7:00 AM EST - 1 year ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Nov 14, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Earnings release: Q3 2024

Aug 23, 2024, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Registration statement: Registration Filing

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Jul 30, 2024, 9:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Jul 26, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Transcript: Study Result

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Press release: Study Result

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Slides: Study Result

Jul 25, 2024, 7:38 AM EDT - 2 years ago

Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

May 17, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 9, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 2, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Apr 24, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Apr 18, 2024, 7:00 AM EDT - 2 years ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Apr 10, 2024, 10:00 AM EDT - 2 years ago

Chemomab Therapeutics Transcript: KOL Event

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Mar 25, 2024, 7:06 AM EDT - 2 years ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Annual report: Q4 2023

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Feb 20, 2024, 7:00 AM EST - 2 years ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Feb 14, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Feb 5, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Jan 30, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Jan 3, 2024, 7:00 AM EST - 2 years ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Nov 16, 2023, 7:00 AM EST - 2 years ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Nov 15, 2023, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Nov 13, 2023, 8:00 AM EST - 2 years ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Nov 9, 2023, 8:00 AM EST - 2 years ago

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Earnings release: Q3 2023

Nov 6, 2023, 4:15 PM EST - 2 years ago

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Registration statement: Registration Filing

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

Psuedo_Doji Jun. 4 at 7:16 PM

$CMMB in Gwen we trust

1 · Reply

Stockhunter008 Jun. 4 at 5:57 PM

$CMMB if nothing else, the recent $CMMB BOD changes are evidence that this company will undoubtedly be monetized

1 · Reply

DLTT4489 Jun. 4 at 5:47 PM

$CMMB he lost tons of money on $QNCX and will do same here. Keep covering each other pumpers 🤣🤣🤣

0 · Reply

DLTT4489 Jun. 4 at 5:44 PM

$CMMB @W2Cap will understand that bought wrong stock soon. Look ar shreyvakil answer. I've been saying these for years and no one believed it, so you deserve to be rubbed by mafia. 😜😜

0 · Reply

DLTT4489 Jun. 4 at 5:36 PM

$CMMB is @Snptrader idiot still posting BS here?? What about @shreyvakil ?? 😅😅

0 · Reply

JoeShmoDoe Jun. 3 at 8:29 PM

$CMMB lol, check history. People should know that no one buys this load of shit.

0 · Reply

JoeShmoDoe Jun. 3 at 8:26 PM

$CMMB lol, the joke happened here. No one literally buys this shit.

0 · Reply

DLTT4489 Jun. 3 at 6:18 PM

$CMMB you don't know those MFrs who's sitting in their office in !z r@el and keep stealing your money. They are blood suckers

0 · Reply

Tigerfromasia Jun. 3 at 2:45 PM

2 · Reply

W2Cap Jun. 3 at 11:11 AM

3 · Reply

Zdxss1 Jun. 3 at 1:26 AM

$CMMB Chemomab has yet to publicly release the results of its May 30th conference to the market, despite the company's promise to present new data there. What has been officially released is a preliminary announcement of three scientific abstracts to be presented at the European Liver Congress (EASL 2026) in Barcelona, but details of this data have not yet been published for investors. Why the delay?

1 · Reply

Rolex53 Jun. 3 at 1:12 AM

$CMMB Also no response from IR on next plans so far.

0 · Reply

Rolex53 Jun. 3 at 1:10 AM

$CMMB I wonder whether the supreme of this company bought few grands of shares just to push the price up and then do offering because this is a new trend of begging. Crap!

0 · Reply

Rolex53 Jun. 3 at 1:08 AM

$CMMB By the time, these guys announce some fluffy news, market will be in deep red IMHO. Thats how these guys choose timings. Like a stupid I invested life savings. Following AC is a blunder of my life. Atleast save us this time. Staying at an average of approx. 20. Show some mercy.

1 · Reply

Zdxss1 Jun. 3 at 12:55 AM

$CMMB Release of news is well-studied and highly tactical. For example, bad news is released on Friday so that the impact is mitigated. Good news is released on Monday to give momentum throughout the entire week. The CEO purchasing a small number of shares is poorly timed when the market is anticipating a partnership announcement, and issuing it on a Monday. This is not a random act, but a deliberate plan to drive the stock price down.

2 · Reply

cpatel2000 Jun. 2 at 10:01 PM

$CMMB Gwen Melincoff joining the Chemomab board on June 1, 2026 is the single most important development since the EOP2 meeting in December 2024. A deal is being actively structured. The board has been reconfigured to support it. The scientific campaign has been completed. The CEO has expressed personal financial conviction. The announcement is coming.

0 · Reply

shreyvakil Jun. 2 at 8:24 PM

$CMMB someone is trying a hostile takeover? Not surprised, and good to cover their bases

1 · Reply

focafoca99 Jun. 2 at 8:11 PM

$CMMB brought on Gwen Melincoff as a new Class I director and chair of the nominating committee.

1 · Reply

DLTT4489 Jun. 2 at 7:52 PM

$CMMB

0 · Reply

Stockhunter008 Jun. 2 at 6:42 PM

it is 2:40 PM EDT. $CMMB has not traded a single share in over an hour and a half ago (since 1 pm). there were over 10,000 shares on the bid 10 minutes ago but now there are 100 shares on the bid. LOL

1 · Reply

Stockhunter008 Jun. 2 at 4:59 PM

$CMMB the CEO buys shares for the first time in many years and the stock promptly drops 15% lol

1 · Reply

Snptrader Jun. 2 at 3:41 PM

$CMMB added a few here..

1 · Reply

Market Cap	12.37M
Revenue (ttm)	0.00
Net Income (ttm)	-9.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	31,600
Avg Vol	43,190
Day's Range	N/A - N/A
Shares Out	7.19M
Stochastic %K	26%
Beta	0.62
Analysts	Strong Sell
Price Target	$15.00